image description

Tag: vobarilizumab

Ablynx Announces Topline Results from the Phase II Study of Vobarilizumab in Patients with Systemic Lupus Erythematosus

March 26, 2018 Source: Ablynx Press Release 3.26.18 Ablynx today announced that the Phase II dose-ranging study of vobarilizumab, the Company’s anti-IL-6R Nanobody®, did not meet the primary endpoint of dose response based on the modified BILAG-based combined lupus assessment (mBICLA) at Week 24. The primary endpoint of the study was the percentage of subjects who […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates